HYKU Biosciences
Laura Brass - Director
Adam Cotton - Observer
Platform
Boston, USA
HYKU Biosciences is developing small-molecule covalent inhibitors targeting non-cysteine amino acids to address current challenges associated with many disease targets, including selectivity, druggability, and resistance.